Cardiopulmonary exercise test-based assessment of the effects of sacubitril/valsartan on the blood pressure response to exercise in patients with acute myocardial infarction during hospitalization

References

• Mogensen UM, Køber L, Kristensen SL, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, et al. PARADIGM-HF Investigators and Committees. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J. 2017 Jun;188:35–41. doi:10.1016/j.ahj.2017.02.034. Epub 2017 Mar 14. PMID: 28577679.
   PubMed Web of Science ®Google Scholar
• Wang H, Fu X. Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coron Artery Dis. 2021 Aug 1;32(5):418–26. doi:10.1097/MCA.0000000000000932. PMID: 32732515.
   PubMed Web of Science ®Google Scholar
• Giallauria F, Di Lorenzo A, Venturini E, Pacileo M, D’Andrea A, Garofalo U, De Lucia F, Testa C, Cuomo G, Iannuzzo G, et al. Frailty in Acute and Chronic Coronary Syndrome Patients Entering Cardiac Rehabilitation. J Clin Med. 2021 Apr 15;10(8):1696. doi:10.3390/jcm10081696. PMID: 33920796; PMCID: PMC8071180.
   PubMed Web of Science ®Google Scholar
• Marinus N, Vigorito C, Giallauria F, Haenen L, Jansegers T, Dendale P, Feys P, Meesen R, Timmermans A, Spildooren J, et al. Frailty is highly prevalent in specific cardiovascular diseases and females, but significantly worsens prognosis in all affected patients: a systematic review. Ageing Res Rev. 2021 Mar;66:101233. doi:10.1016/j.arr.2020.101233. Epub 2020 Dec 14. PMID: 33333322.
   PubMed Web of Science ®Google Scholar
• An J, Du Y, Li X, Bao Q, Guo Y, Song Y, Jia Y. Myocardial protective effect of sacubitril-valsartan on rats with acute myocardial infarction. Perfusion. 2021 Jan;31:267659121990572. doi:10.1177/0267659121990572. Epub ahead of print. PMID: 33522428.
   Google Scholar
• Xiong B, Nie D, Qian J, Yao Y, Yang G, Rong S, Zhu Q, Du Y, Jiang Y, Huang J. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC Heart Fail. 2021 Oct 30;8(6):4852–62. doi:10.1002/ehf2.13677. Epub ahead of print. PMID: 34716749.
   PubMedGoogle Scholar
• Turski M, Kocierz-Woźnowska M, Wybraniec M, Grabka M, Wita M, Berger-Kucza A, Wita K, Mizia-Stec K. Factors determining exercise capacity evaluated during cardiopulmonary exercise testing in 6-month follow-up after ST elevation myocardial infarction. Clin Physiol Funct Imaging. 2019 May;39(3):209–14. doi:10.1111/cpf.12560. Epub 2019 Jan 17. PMID: 30589484.
   PubMed Web of Science ®Google Scholar
• Malfatto G, Ravaro S, Caravita S, Baratto C, Sorropago A, Giglio A, Tomaselli M, Parati G, Villani A. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test. Acta Cardiol. 2020 Dec;75(8):732–36. doi:10.1080/00015385.2019.1669317. Epub 2019 Oct 2. PMID: 31577528.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu Y, Zhang K, Ke Z, Hu P, Jin D. Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Coron Artery Dis. 2021 Aug 1;32(5):427–31. doi:10.1097/MCA.0000000000000955. PMID: 32868662.
   PubMed Web of Science ®Google Scholar
• Rezq A, Saad M, El Nozahi M. Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2021 Mar 15;143:7–13. doi:10.1016/j.amjcard.2020.12.037. Epub 2021 Jan 6. PMID: 33417876.
   PubMed Web of Science ®Google Scholar
• Rovai S, Corrà U, Piepoli M, Vignati C, Salvioni E, Bonomi A, Mattavelli I, Arcari L, Scardovi AB, Perrone Filardi P, et al., MECKI Score Research Group (see Appendix 1). Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. Eur J Heart Fail. 2019 Dec;21(12): 1586–95. doi:10.1002/ejhf.1595. Epub 2019 Nov 28. PMID: 31782225.
   PubMed Web of Science ®Google Scholar
• Nakade T, Adachi H, Murata M, Oshima S. Relationship Between Exercise Oscillatory Ventilation Loop and Prognosis of Heart Failure. Circ J. 2019 Jul 25;83(8):1718–25. doi:10.1253/circj.CJ-18-1047. Epub 2019 Jun 28. PMID: 31257356.
   PubMed Web of Science ®Google Scholar
• Giallauria F, Vitale G, Pacileo M, Di Lorenzo A, Oliviero A, Passaro F, Calce R, Parlato A, Testa C, D’Ambrosio G, et al. Sacubitril/valsartan improves autonomic function and cardiopulmonary parameters in patients with heart failure with reduced ejection fraction. J Clin Med. 2020 Jun 17;9(6):1897. doi:10.3390/jcm9061897. PMID: 32560431; PMCID: PMC7356720.
   Web of Science ®Google Scholar
• Soh MS, Park JS, Seo KW, Yang HM, Lim HS, Choi BJ, Choi SY, Yoon MH, Hwang GS, Tahk SJ, et al. Visit-to-visit systolic blood pressure variability in patients with ST-elevation myocardial infarction predicts long-term cardiovascular outcomes. J Hum Hypertens. 2019 Apr;33(4):259–66. doi:10.1038/s41371-019-0176-0. Epub 2019 Feb 18. PMID: 30778130; PMCID: PMC6760754.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Claggett B, Minamisawa M, Nochioka K, Mitchell GF, Anand IS, Zannad F, Shah SJ, Lefkowitz M, Shi V, et al. Pulse pressure, prognosis, and influence of sacubitril/valsartan in heart failure with preserved ejection fraction. Hypertension. 2021 Feb;77(2):546–56. doi:10.1161/HYPERTENSIONAHA.120.16277. Epub 2020 Dec 28. PMID: 33356401.
   PubMed Web of Science ®Google Scholar
• Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019 Jan;21(1):67–76. doi:10.1111/jch.13437. Epub 2018 Dec 11. PMID: 30536595.
   PubMed Web of Science ®Google Scholar
• Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022 Jan 21. doi:10.1038/s41440-021-00819-7. Epub ahead of print. PMID: 35058583.
   Google Scholar
• Anderson SL, Marrs JC. Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment. Drugs Context. 2018 Aug 6;7:212542. doi:10.7573/dic.212542. PMID: 30116284; PMCID: PMC6089617.
   PubMedGoogle Scholar
• Chang PC, Wo HT, Lee HL, Lin SF, Chu Y, Wen MS, Chou CC. Sacubitril/valsartan therapy ameliorates ventricular tachyarrhythmia inducibility in a rabbit myocardial infarction model. J Card Fail. 2020 Jun;26(6):527–37. doi:10.1016/j.cardfail.2020.03.007. Epub 2020 Mar 21. PMID: 32209390.
   PubMed Web of Science ®Google Scholar